Serum M65 as a Biomarker for Metastatic Renal Cell Carcinoma |
| |
| Authors: | Ibrahim Yildiz Fatma Sen Leyla Kilic Serkan Keskin Derya Duranyildiz Elif Bilgin Rian Disci Meltem Ekenel Emin Darendeliler Sevil Bavbek Mert Basaran |
| |
| Affiliation: | 1. INSERM UMRS 699, Paris, France;2. Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d’Excellence INFLAMEX, Paris, France;3. Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden;4. INSERM U986, Hôpital Cochin/Saint-Vincent de Paul, Paris, France;5. Université Paris Descartes, Paris, France;6. Sorbonne Paris Cite, Laboratoire d’Excellence INFLAMEX, Paris, France;7. Service de Néphrologie, Hôpital Universitaire Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France;1. James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Boston, MA;2. Department of Pathology, Harvard Medical School, Boston, MA;3. Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People’s Republic of China;4. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China;5. Department of Urology, Guangzhou First Municipal People’s Hospital, Guangzhou Medical College, Guangzhou, People’s Republic of China;6. Department of Urology, Massachusetts General Hospital, Boston, MA;1. Departments of Genitourinary Medical Oncology;2. Biostatistics;3. Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA |
| |
| Abstract: | Introduction/BackgroundEffective cancer biomarkers for early detection, prognosis, or therapy response prediction are urgently need in metastatic RCC. M30 and M65 are released during apoptotic cell death and precisely reflect epithelial tumor cell death. The aim of this study was to determine the prognostic value of plasma M30 and M65 levels in predicting survival rates for patients with metastatic RCC.Patients and MethodsThirty-nine patients with metastatic RCC and 39 healthy control subjects were included in this study. Serum M30 and M65 levels were measured by ELISA.ResultsThe median ages of the patients and control subjects were 60 and 58 years, respectively. No difference was detected in the median serum M30 level between the patients and control subjects (53.7 vs. 49.1 U/L; P = .31). The median serum M65 level was significantly higher in patients than in control subjects (334.0 vs. 179.1 U/L; P < .001). Receiver operating characteristic analysis revealed that the best cutoff value for serum M65 level for predicting progression-free survival (PFS) was 313.6 U/L. The median PFS of patients whose M65 levels were ≤ 313.6 U/L was better than that of patients whose M65 levels were > 313.6 U/L (P = .03).ConclusionTo the best of our knowledge, this is the first study to evaluate serum M30 and M65 levels in patients with RCC. Serum M65 levels were significantly elevated in patients with metastatic RCC compared with healthy individuals. In addition, the serum M65 level could be predictive of PFS in patients with RCC. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
